Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.39 |
| ▸ | HTR3B | O95264 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526372 | 0.74 | PLD1 (0.44) | PLD1ADRB2NCF1ALDH1A1KDM4E | |
| SCHEMBL17595113 | 0.70 | PLD1 (0.53) | PLD1ADRB2NCF1ALDH1A1KDM4E | |
| SCHEMBL4677595 | 0.65 | ADRB1 (0.41) | PLD1ADRB2NCF1HTR3EHTR3B | |
| SCHEMBL194631 | 0.65 | PLD1 (0.62) | PLD1ADRB2NCF1HTR3EHTR3B | |
| SCHEMBL8010836 | 0.65 | HRH4 (0.40) | PLD1ADRB2NCF1ALDH1A1KDM4E | |
| SCHEMBL15416277 | 0.64 | PLD1 (0.39) | PLD1ADRB2NCF1ALDH1A1KDM4E | |
| SCHEMBL15416096 | 0.64 | ADRB1 (0.49) | PLD1ADRB2NCF1ALDH1A1BPTF | |
| SCHEMBL2439624 | 0.64 | BPTF (0.53) | PLD1ADRB2NCF1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL20424251 | 0.64 | PLD1 (0.60) | PLD1ADRB2NCF1ALDH1A1KDM4E | |
| Water SCHEMBL27506673 | 0.63 | BPTF (0.51) | PLD1ADRB2NCF1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4416817-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-11-22 | — | — | US | claimed |
| CN-106132956-B | Heterocyclic compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2019-12-10 | — | — | CN | disclosed |
| EP-3149008-A1 | CERTAIN PROTEIN KINASE INHIBITORS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015180642-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-12-03 | — | — | WO | disclosed |
| US-8093238-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-01-10 | — | — | US | disclosed |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-2076512-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008044022-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | JAK1, MTOR, MOK | PLD1 2547/4885ADRB2 3652/4885NCF1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.